21.08.2018
Dermapharm Holding SE DE000A2GS5D8
DGAP-News: Dermapharm Holding SE:
DGAP-News: Dermapharm Holding SE / Key word(s): Half Year
Results/Preliminary Results
Dermapharm Holding SE:
21.08.2018 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Dermapharm continues profitable growth in first half of 2018
* Group revenues increased by around 20% from last year to EUR 280.3
million
* Adjusted EBITDA increased by around 30% over last year to EUR 70.9
million
* Adjusted EBITDA margin improved by about 2% from last year to approx.
25%
* Management Board confirms previous forecast for fiscal year 2018
Grünwald, August 21, 2018 - Dermapharm Holding SE ("Dermapharm"), a leading
producer of patent-free branded pharmaceuticals for select therapeutic areas
based in Germany with a growing international presence, published its
unaudited preliminary IFRS financial figures for the first half of 2018
today. Both the highly profitable segment "Branded Pharmaceuticals and Other
Healthcare Products" and the "Parallel Import Business" contributed to the
rise in revenues and earnings.
On a preliminary basis, Group revenues rose by 19.7% to EUR 280.3 million in
the first half of 2018 (previous year: EUR 234.2 million). Dermapharm also
significantly improved its earnings before interest, taxes, depreciation and
amortization (EBITDA) in the first half of 2018. The company's EBITDA
adjusted for one-off costs amounting to EUR 1.4 million related to IPO
preparations and the acquisitions of Strathmann and Trommsdorff in the
amount of EUR 2.4 million increased by 29.9% to EUR 70.9 million (previous
year: EUR 54.6 million). Dermapharm was therefore able to continue
increasing its rising profitability in the first half of 2018, achieving an
adjusted EBITDA margin at Group level of 25.3% (same period of the previous
year: 23.3%). Unadjusted EBITDA amounted to EUR 67.1 million, an increase of
22.9% compared to the same period of the previous year, and an unadjusted
EBITDA margin of 23.9%.
Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE, explains the course
of business in the first half of 2018: "The figures for the first six months
of the current fiscal year reflect the success of our consistent growth
strategy. With our latest acquisitions of Strathmann and Trommsdorff, we
have not only expanded our current portfolio with established brand products
such as Keltican(R) forte, but have also gained a significant market share
in a new therapeutic area. The therapeutic area of pain treatment rounds off
our strategic therapeutic areas, which include dermatologics, systemic
corticoids, women's healthcare, ophthalmologics and vitamins, minerals and
enzymes. With Myopridin(R) and Ebenol(R) from Strathmann, our portfolio now
includes ambitious products in this new market. In addition, Dermapharm
achieved further market approvals in the first half of the year, such as
Verrucutan(R), Calcilac mono(R) or Summavit materna(R), and is also working
on more than 40 ongoing development projects. We have also succeeded in
opening up new European markets for our hyperthermia products bite away(R)
and Herpotherm(R) in Northern, Eastern and Central Europe and plan to market
the products in the UK, Western Europe, Asia and the US in the future."
In light of the positive business development in the first half of 2018, the
Management Board of Dermapharm Holding SE can confirm its previous forecast
for fiscal year 2018 and continues to assume revenue growth of 20 to 25%
over the previous year and an increase in adjusted EBITDA of 22 to 27% over
the previous year. Dermapharm is pursuing its objective of consistently
using both organic and external growth opportunities to become the leading
European pharmaceutical producer in select markets.
Dermapharm will publish the final figures for the first half of 2018 with
its complete interim report for 2018 on September 12, 2018.
Group revenues and EBITDA as of June 30, 2018, compared to the same period
of the previous year (IFRS, preliminary)
in EUR millions June 30, 2018 June 30, 2017 Change
Group revenues 280.3 234.2 + 19.7%
Adjusted Group EBITDA* 70.9 54.6 + 29.9%
Adjusted EBITDA margin* (in %) 25.3 23.3 + 2.0pp
Group EBITDA 67.1 54.6 + 22.9%
EBITDA margin (in %) 23.9 23.3 + 0.6pp
*Adjusted for one-off costs amounting to EUR 1.4 million in connection with
the IPO and the acquisitions of Strathmann and Trommsdorff in the amount of
EUR 2.4 million.
Company profile:
Dermapharm - Pharmaceutical Excellence "Made in Germany"
Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals
for selected markets in Germany. Founded in 1991, the company is based in
Grünwald near Munich and has its main manufacturing facility in Brehna near
Leipzig. The company's integrated business model comprises in-house
development, in-house production and distribution of pharmaceuticals and
other healthcare products for specifically targeted markets by a medical and
pharmaceutical sales force. Dermapharm holds approximately 950 marketing
authorizations (Arzneimittelzulassungen) for more than 250 active
pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary
supplements or supplemental balanced diets. This assortment makes the
company unique. In addition to Germany, the company's core markets also
include Austria and Switzerland. The company plans to further expand its
international presence. Dermapharm's business model also includes a parallel
import business, which operates under the "axicorp" brand. Based on
revenues, Dermapharm was among the top five parallel import companies in
Germany in the first half-year 2018.
With a consistent development strategy and numerous successful product and
company acquisitions over the past 25 years, Dermapharm has continuously
optimized its business and provided external growth impulses in addition to
organic growth. Dermapharm intends to continue this profitable growth course
in the future. The company is focusing on three strategic growth drivers:
in-house development of new products, increase of its international
footprint and further acquisitions. These include the acquisition of the
pharmaceuticals manufacturer and distributor Trommsdorff in January 2018,
whose portfolio includes the well-known brands Keltican(R) forte and
Tromcardin(R) complex.
Contact
cometis AG
Claudius Krause
Phone: +49 (0)611 - 205855-28
Fax: +49 (0)611 - 205855-66
E-mail: [email protected]
---------------------------------------------------------------------------
21.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: [email protected]
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Stuttgart,
Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
715759 21.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Dermapharm Holding SE ISIN: DE000A2GS5D8 können Sie bei EQS abrufen
Gesundheit , A2GS5D , DMP , XETR:DMP